US · Health Care
Lilly (Eli) stock overview: financials, insider activity, and peer context
Lilly (Eli) operates in the Pharmaceuticals industry within the Health Care sector and is a constituent of the S&P 500. This page connects filing evidence with ownership, insider activity, forecasts, ETFs, and peer context so each dataset can be checked against the others.
Deterministic, source-linked commentary
The current research read on LLY
For LLY, the filing evidence matters before the market narrative. 10-Q covers CY2026Q1. quarterly revenue was $19.8B; year-over-year growth was 55.5%; trailing free cash flow was $8.6B. Read together, these figures test whether scale is translating into profit and cash. Verify periods and company footnotes in the original SEC EDGAR filing.
No single dataset settles the LLY research case. Use institutional ownership, insider filings alongside the filing. Company facts can update before 13F positions, so align every source date and report period before treating a difference as a change in fundamentals.
Business model
Company snapshot
Lilly (Eli) operates in the Pharmaceuticals industry within the Health Care sector and is a constituent of the S&P 500. The latest standardized snapshot records $65.69B of trailing revenue, $21.4B of net income, and $8.61B of free cash flow. These figures describe the reported company, while valuation and price require a separate market-data timestamp.
Operating lines
A named product, service, or operating exposure identified in the company description.
A named product, service, or operating exposure identified in the company description.
Geographic revenue mix
The current standardized filing dataset does not extract a comparable geographic revenue table for every issuer. Review the latest 10-K segment note for domestic and international mix, concentration, foreign-exchange sensitivity, and country-specific regulation.
10-Q · 2026-04-30
What the latest filing shows
Revenue for the latest standardized quarter was $19.8B, while diluted EPS was 8.26. Revenue changed 55.5% from the comparable period. Gross margin was 81.9% and operating margin was N/A. Margin direction matters because it shows whether growth is translating into operating leverage or requiring more cost to support.
Open original SEC filingCY2026Q1
Earnings analysis
| Period | Revenue | Net income | EPS | Operating margin |
|---|---|---|---|---|
| CY2026Q1 | $19.8B | $7.4B | 8.26 | N/A |
| TTM | $65.69B | $21.4B | 23.82 | N/A |
| CY2025 | $65.18B | $20.64B | See filing | N/A |
The standardized data shows revenue growth of 55.5%, an operating margin of 0%, and a net margin of 32.6%. Without a dedicated earnings article, the original filing remains the primary source for management guidance and expectation comparisons.
Health Care
Peer comparison
| Company | TTM revenue | Revenue growth | Operating margin | Tracked holders |
|---|---|---|---|---|
| LLYLilly (Eli) | $65.69B | 55.5% | N/A | 0 |
| MRKMerck & Co. | $64.9B | 4.9% | N/A | 0 |
| HCAHCA Healthcare | $75.2B | 4.3% | N/A | 0 |
| BMYBristol Myers Squibb | $47.18B | 2.6% | N/A | 0 |
| JNJJohnson & Johnson | $93.69B | 9.9% | 26% | 0 |
| ABTAbbott Laboratories | $44.03B | 7.8% | 16.2% | 0 |
| TMOThermo Fisher Scientific | $43.35B | 6.2% | 17% | 0 |
LLY's 55.5% revenue growth and 0% operating margin should be read against peers using the same reporting definitions. A higher margin may reflect pricing power or business mix, while a lower margin can reflect investment, cyclicality, or weaker economics.
Fund ownership
ETF exposure
LLY appears among the disclosed top holdings of 9 tracked ETFs shown below. ETF weights change with price movement, rebalancing, creations, redemptions, and issuer methodology.
| ETF | LLY weight | AUM | Holdings date |
|---|---|---|---|
| VUGVanguard Growth ETF | 2.31% | $224.72B | Apr 30, 2026 |
| IWFiShares Russell 1000 Growth ETF | 2.56% | $128.66B | May 19, 2026 |
| VIGVanguard Dividend Appreciation ETF | 3.32% | $106.65B | Apr 30, 2026 |
| SCHGSchwab U.S. Large-Cap Growth ETF | 2.81% | $59.19B | May 19, 2026 |
| MGKVanguard Mega Cap Growth ETF | 2.82% | $33.53B | Apr 30, 2026 |
| IUSGiShares Core S&P U.S. Growth ETF | 2.23% | $31.49B | May 19, 2026 |
| XLVState Street Health Care Select Sector SPDR ETF | 14.86% | $37.46B | May 18, 2026 |
| VHTVanguard Health Care ETF | 12.13% | $16.09B | Apr 30, 2026 |
| QUALiShares MSCI USA Quality Factor ETF | 3.15% | $51.10B | May 19, 2026 |
10-K · 2026-02-12
Key risk factors disclosed in the latest 10-K
The categories below are a deterministic research checklist anchored to Lilly (Eli)'s industry and latest annual filing. They summarize areas investors should locate in Item 1A; they do not replace the company's exact legal disclosure.
- Demand and product-cycle risk: Pharmaceuticals can experience changing customer demand, replacement cycles, and competitive product launches that affect revenue timing.
- Competition and execution: Market share depends on product quality, pricing, distribution, innovation, and management's ability to convert investment into durable customer demand.
- Supply chain and counterparties: Supplier concentration, logistics disruption, component availability, and customer concentration can affect delivery schedules, costs, and working capital.
- Regulation and litigation: Antitrust, privacy, securities, labor, tax, environmental, and industry-specific rules may change costs or restrict products and business practices.
- Financial and market risk: Foreign exchange, interest rates, credit conditions, investment values, and capital-allocation decisions can affect reported earnings and valuation.
Shareholder returns
Dividend and buyback history
Dividend
Lilly (Eli) reported $5.41B of dividends paid over the trailing period and $1.55B in the latest standardized quarter. These are company cash outflows, not a per-share forward yield.
Share buybacks
The standardized snapshot does not currently expose a reliable repurchase authorization and share-count bridge for every issuer. Compare diluted shares outstanding across filings and read the capital-return note before concluding that buybacks reduced the share base.
Research workflow
Common research questions about LLY
Who is the largest tracked institutional holder of LLY?
The current tracked-manager sample does not identify an active LLY holder. The LLY ownership page will reflect a matching position when one enters the filing dataset.
What does recent insider activity show for LLY?
No recent Form 4 transaction appears in the current LLY window. Check the LLY Form 4 history for later company-officer or director filings.
What business does Lilly (Eli) operate?
Lilly (Eli) operates in the Pharmaceuticals industry within the Health Care sector and is a constituent of the S&P 500. The LLY company snapshot connects that business description with reported revenue, profit, and cash flow.
How does LLY compare with a close operating peer?
LLY's revenue growth is 55.5% and its operating margin is not separately available. Compare those figures with MRK research using the same definitions.
What do the latest financials say about LLY?
10-Q reports $65.7B of trailing revenue, with revenue growth of 55.5%. The supporting period and source are listed in the LLY filing section.
How strong is LLY's cash return profile?
Lilly (Eli) reported $5.4B of trailing dividends paid alongside $8.6B of free cash flow. The LLY capital-return section separates company cash outflows from a forward per-share yield.
Which reported changes matter most for the LLY outlook?
Without a dedicated forecast, the key LLY evidence is the direction of revenue, margin, cash flow, and company guidance. The LLY earnings section keeps those reported changes together.
Primary and reference data
Sources and methodology
- Filings: SEC EDGAR CompanyFacts, 10-K, 10-Q, 8-K, Form 4, 13F-HR.
- Fundamentals: SEC EDGAR CompanyFacts; market references may use yfinance and Finnhub where explicitly available.
- ETF: Issuer disclosures and the locally dated ETF holdings snapshot.
Methodology: How SnowballHare parses and validates data.
Editorial standards: How research is published.
Disclaimer: Informational only; not investment, legal, or tax advice. Cross-check material facts against original filings before acting.
Reference notes
Data notes
Reporting dates
Use filing dates, report periods, and source links together for LLY. A company filing, a 13F disclosure, a Form 4 transaction, and an earnings release can describe different time windows, so the date beside each row matters before comparing signals.
Ownership context
13F rows are delayed public long-equity snapshots from a selected manager universe. They are useful for seeing which tracked institutions reported exposure, but they do not show every hedge, short position, cash balance, or trade made after the quarter ended.
Insider transactions
Form 4 activity should be read by transaction type, role, value, and remaining ownership. Open-market purchases and sales are different from grants, option exercises, gifts, or tax withholding, and the original SEC filing is still the controlling document.
Earnings and forecasts
Earnings pages and forecast pages are linked when a supported article exists. Treat those pages as context for reported numbers, guidance, margins, and scenario assumptions, then return to the table data when you need the underlying source date or filing trail.